About The Study: This cross-sectional study found that glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and misuse were common in a targeted sample of people with eating disorders. The prevalence of lifetime GLP-1 RA use was higher among people with eating disorders than the 15% observed in the general adult population. People with eating disorders are a clinically diverse population who may be consuming GLP-1 RAs in contraindicated ways to maintain eating disorder psychopathology through rapid restriction and weight loss.
Corresponding Author: To contact the corresponding author, Nicholas C. Peiper, PhD, MPH, email nicholas.peiper@louisville.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(10.1001/jamapsychiatry.2026.1716)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1716?guestAccessKey=b318a96e-d60a-4ba7-a59e-51eda11620e3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062426
Journal
JAMA Psychiatry